Immunosuppression after renal allograft failure: a survey of US practices

• Published in: Clinical transplantation 2013-11, Vol.27 (6), p.895-900
• Main Authors: Bayliss, George P., Gohh, Reginald Y., Morrissey, Paul E., Rodrigue, James R., Mandelbrot, Didier A.
• Format: Article
• Language: English
• Subjects: Adult; Allografts; Biological and medical sciences; Child; Follow-Up Studies; graft failure; Graft Rejection - drug therapy; Graft Rejection - etiology; Graft Survival; Humans; Immunomodulators; Immunosuppression; Immunosuppressive Agents - therapeutic use; Kidney Failure, Chronic - surgery; Kidney Transplantation; Medical sciences; Pharmacology. Drug treatments; Practice Patterns, Physicians; Prognosis; renal transplantation; Risk Factors; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system; Surveys and Questionnaires
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/ctr.12254

Background Little data exist to guide the management of immunosuppression after renal graft failure. More aggressive tapering of immunosuppressive medications may reduce the risk of infection, but may increase the risk of rejection and sensitization. Methods To document current practices in the US, we emailed a questionnaire to medical and surgical transplant directors as identified by the United Network for Organ Sharing (UNOS). Results Emails were sent to 221 programs, of which 93 (42.1%) responded. About 24.7% of respondents reported adjusting immunosuppression according to a standard protocol; 75.3% said practices are physician dependent. The majority said that 80 or 100% of patients are off all immunosuppression one yr after returning to dialysis. The most important factors cited in deciding whether to stop immunosuppression were plans to retransplant (40.2%) and signs and symptoms of rejection (37.0%). When asked which immunosuppressive medications are continued indefinitely, 21.5% responded prednisone and 71.0% said none. Respondents most commonly said they performed graft nephrectomy only if there are signs and symptoms of rejection (47.3%) or if signs and symptoms of rejection fail to respond to steroids (34.4%). Conclusions In the absence of good data to guide decisions on immunosuppression in patients with failed allografts, practices in the US vary greatly. More data are needed to determine which policies lead to the best outcomes.